{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-25-000101","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.653981+00:00","generated_at":"2026-05-17T04:23:32.179922+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"BioMarin expects $221M IPR&D charge from Inozyme acquisition, ~$1.10 EPS hit in Q3 2025","bullets":["Acquired IPR&D charge of ~$221M pre-tax from July 1 Inozyme Pharma acquisition.","Charge reduces both GAAP and Non-GAAP diluted EPS by approximately $1.10 for Q3 2025.","Q3 2025 results not finalized; actual results may differ from preliminary estimates.","BioMarin does not forecast IPR&D charges due to uncertainty of timing and magnitude."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-25-000101","json":"https://secwatch.observer/filing/0001048477-25-000101.json","markdown":"https://secwatch.observer/filing/0001048477-25-000101.md","text":"https://secwatch.observer/filing/0001048477-25-000101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000101/0001048477-25-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000101/bmrn-20251007.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:23:32.179922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}